LA JOLLA, Calif.--(BUSINESS WIRE)--A catalytic antibody discovery made at The Scripps Research Institute has formed the basis of the upcoming acquisition of biotechnology venture CovX by pharmaceutical giant Pfizer, Inc.
LA JOLLA, Calif.--(BUSINESS WIRE)--A catalytic antibody discovery made at The Scripps Research Institute has formed the basis of the upcoming acquisition of biotechnology venture CovX by pharmaceutical giant Pfizer, Inc.
